Showing 1 posts of 1 posts found.
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival (OS) and progression-free survival (PFS) …
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
MHRA awards Innovation Passports to liver cancer and dementia medicines
Scottish NHS hospital adopts light-activated therapy to reduce surgical infections
Manchester launches nurse-led clinic to improve kidney transplant outcomes
Androlabs and Majorelle expand testosterone therapy into France